Streptococcal C5a peptidase vaccine
AssigneeRegents of the University of Minnesota
InventorsPaul Patrick Cleary, Deborah K. Stafslien
Life of this patent
Estimating the term…
Abstract
Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of strepococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
Claims29
A vaccine comprising an immunogenic amount of an enzymatically inactive streptococcal C5a peptidase (SCP), wherein the SCP is a variant of wild-type SCP, which amount is effective to immunize a susceptible mammal against β-hemolytic Streptococcus in combination with a physiologically-acceptable, non-toxic vehicle, wherein the SCP has a modification at one or more of amino acid residues 260, 261, 262, 415, 416, 417, 130, 193, 295 or 512.
Dependencies are inferred from the claim text.